| # | Title | Journal | Year | Citations |
|---|
| 1 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Lancet, The | 2018 | 3,542 |
| 2 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Lancet Oncology, The | 2018 | 1,816 |
| 3 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib | JAMA Oncology | 2020 | 746 |
| 4 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma | Journal of Clinical Oncology | 2020 | 723 |
| 5 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC | Nature | 2021 | 649 |
| 6 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | Journal of Hepatology | 2022 | 568 |
| 7 | JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan | Liver Cancer | 2014 | 512 |
| 8 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) | Annals of Oncology | 2019 | 512 |
| 9 | Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial | Gut | 2020 | 411 |
| 10 | Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection | Journal of Hepatology | 2018 | 360 |
| 11 | The role of hepatic resection in the treatment of hepatocellular cancer | Hepatology | 2015 | 310 |
| 12 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | Journal of Hepatology | 2020 | 310 |
| 13 | Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update | Liver Cancer | 2021 | 307 |
| 14 | Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | | 2022 | 298 |
| 15 | Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma | Journal of Gastroenterology | 2017 | 275 |
| 16 | Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference | Hepatology | 2021 | 235 |
| 17 | Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. | Journal of Clinical Oncology | 2022 | 235 |
| 18 | Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver–Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS | Ultrasound in Medicine and Biology | 2020 | 210 |
| 19 | Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study | Cancers | 2019 | 200 |
| 20 | Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial | Annals of Oncology | 2019 | 195 |
| 21 | Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials | Oncology | 2017 | 180 |
| 22 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Journal of Hepatology | 2019 | 180 |
| 23 | Covered Self-Expandable Metal Stents With an Anti-Migration System Improve Patency Duration Without Increased Complications Compared With Uncovered Stents for Distal Biliary Obstruction Caused by Pancreatic Carcinoma: A Randomized Multicenter Trial | American Journal of Gastroenterology | 2013 | 179 |
| 24 | Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial | Lancet Oncology, The | 2021 | 179 |
| 25 | Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC | Journal of Hepatology | 2017 | 178 |
| 26 | Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma | Liver Cancer | 2015 | 172 |
| 27 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements | Liver Cancer | 2020 | 172 |
| 28 | Computer-Aided Diagnosis Based on Convolutional Neural Network System for Colorectal Polyp Classification: Preliminary Experience | Oncology | 2017 | 167 |
| 29 | Multicenter study of early pancreatic cancer in Japan | Pancreatology | 2018 | 165 |
| 30 | A comparison of the resection rate for cold and hot snare polypectomy for 4–9 mm colorectal polyps: a multicentre randomised controlled trial (CRESCENT study) | Gut | 2018 | 162 |
| 31 | Signaling Pathways Governing Tumor Angiogenesis | Oncology | 2011 | 159 |
| 32 | Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications | Liver Cancer | 2017 | 159 |
| 33 | Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study | Clinical Cancer Research | 2017 | 150 |
| 34 | IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC) | Annals of Oncology | 2019 | 146 |
| 35 | Immunopathogenesis of pancreatitis | Mucosal Immunology | 2017 | 139 |
| 36 | Systemic Therapy for Hepatocellular Carcinoma: Latest Advances | Cancers | 2018 | 138 |
| 37 | Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond | World Journal of Gastroenterology | 2019 | 135 |
| 38 | FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma | Hepatology | 2013 | 133 |
| 39 | Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis | Cancer Medicine | 2019 | 131 |
| 40 | Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2020 – WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS | Ultraschall in Der Medizin | 2020 | 130 |
| 41 | Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma | Hepatology | 2012 | 129 |
| 42 | Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia | Clinical Cancer Research | 2015 | 128 |
| 43 | Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer | Investigational New Drugs | 2017 | 128 |
| 44 | Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study | The Lancet Gastroenterology and Hepatology | 2018 | 127 |
| 45 | CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis | Journal of Hepatology | 2021 | 127 |
| 46 | Consensus report of the 2nd International Forum for Liver MRI | European Radiology | 2009 | 125 |
| 47 | Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond | Cancer Treatment Reviews | 2018 | 124 |
| 48 | REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset | Journal of Gastroenterology | 2020 | 123 |
| 49 | Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan | Liver Cancer | 2016 | 122 |
| 50 | Long-term outcomes of EUS-guided choledochoduodenostomy using a lumen-apposing metal stent for malignant distal biliary obstruction: a prospective multicenter study | Gastrointestinal Endoscopy | 2018 | 122 |
